Fig. 1: Objective responses, durations of response and representative tumor complete response images.
From: Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

a, Change in tumor size after CT041 in the 36 patients with target lesions. b, Best responses of each patient assessed according to RECIST 1.1 by the investigator, grouped by dose. c, Tumor lesion of the umbilicus in Pt08 disappeared after CT041 infusion as visualized by CT scans and photography. W, week.